We next determined whether the concurrent inhibition of autophagy activities by specific suppression of ATG12, one of the key transcription factors for LC3 expression, could also enhance the anti-cancer effects of EGFR inhibitors in human bladder cancer cells. This evidence concerns the gene MAP1LC3A and urinary bladder cancer.